Symptomatic VTE
Heparin prophylaxis leads to lower symptomatic VTE compared with no prophylaxis (high certainty).
1 finding from 1 review
Symptomatic PE · pregnant women at increased risk of VTE during pregnancy and the early postnatal period
It is very uncertain whether antenatal (± postnatal) prophylaxis: heparin (LMWH or UFH) changes symptomatic PE ( compared with no treatment/placebo (very low certainty).
1 finding from 1 review
Symptomatic DVT · pregnant women at increased risk of VTE during pregnancy and the early postnatal period
It is very uncertain whether antenatal (± postnatal) prophylaxis: heparin (LMWH or UFH) changes symptomatic DVT ( compared with no treatment/placebo (very low certainty).
1 finding from 1 review
Symptomatic thromboembolic events ( · pregnant women at increased risk of VTE during pregnancy and the early postnatal period
It is very uncertain whether antenatal (± postnatal) prophylaxis: heparin (LMWH or UFH) changes symptomatic thromboembolic events ( compared with no treatment/placebo (very low certainty).
1 finding from 1 review
Symptomatic PE · ambulatory cancer patients receiving chemotherapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
DVT (symptomatic, asymptomatic, non‐fatal) · people undergoing major amputation of the lower extremity
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Symptomatic VTE · ambulatory cancer patients receiving chemotherapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Symptomatic DVT · ambulatory cancer patients receiving chemotherapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Symptomatic PE · ambulatory cancer patients receiving chemotherapy
Low‐molecular‐weight heparin probably leads to lower symptomatic PE compared with no thromboprophylaxis (moderate certainty).
1 finding from 1 review
Symptomatic PE · women giving birth by elective or emergency caesarean (elective only (1 trial), emergency or elective (4 trials))
It is very uncertain whether peripartum/postnatal prophylaxis (caesarean): heparin (LMWH or UFH) changes symptomatic PE (timing of assessment unclear, within 6 weeks… compared with no treatment/placebo (very low certainty).
1 finding from 1 review
Symptomatic DVT · women giving birth by elective or emergency caesarean (elective only (1 trial), emergency or elective (4 trials))
1 finding from 1 review
PE (symptomatic, asymptomatic, non‐fatal) · people undergoing major amputation of the lower extremity
Heparin showed no clear difference in PE (symptomatic, asymptomatic, non‐fatal) (timing not specified) compared with placebo (low certainty).
1 finding from 1 review
Symptomatic thromboembolic events ( · women giving birth by elective or emergency caesarean (elective only (1 trial), emergency or elective (4 trials))
It is very uncertain whether peripartum/postnatal prophylaxis (caesarean): heparin (LMWH or UFH) changes symptomatic thromboembolic events (timing of assessment unclear,… compared with no treatment/placebo (very low certainty).
1 finding from 1 review
Symptomatic DVT · ambulatory cancer patients receiving chemotherapy
Low‐molecular‐weight heparin leads to lower symptomatic DVT compared with no thromboprophylaxis (high certainty).
1 finding from 1 review
Symptomatic VTE · ambulatory cancer patients receiving chemotherapy
Low‐molecular‐weight heparin leads to lower symptomatic VTE compared with no thromboprophylaxis (high certainty).
1 finding from 1 review
PE (symptomatic, asymptomatic, non‐fatal) · people undergoing major amputation of the lower extremity
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Symptomatic venous thromboembolism · prevention of venous thromboembolism in patients with lower‐limb immobilization
Low molecular weight heparin may leads to lower symptomatic venous thromboembolism compared with no prophylaxis or placebo (low certainty).
1 finding from 1 review
Symptomatic DVT · participants at risk of venous thromboembolism
1 finding from 1 review
DVT (symptomatic, asymptomatic, non‐fatal) · people undergoing major amputation of the lower extremity
It is very uncertain whether unfractionated heparin changes DVT (symptomatic, asymptomatic, non‐fatal) (5 to 8 days after surgery) compared with low molecular weight heparin (very low certainty).
1 finding from 1 review
Asymptomatic DVT · adults undergoing KA
It is very uncertain whether low‐molecular‐weight heparin changes asymptomatic DVT: compared with no prophylaxis (very low certainty).
1 finding from 1 review